Hims vs Peptivo
Hims and Peptivo sell different medications; this is what separates them.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Hims
Best for: knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC
Visit Hims →
Peptivo
Best for: seeing what it charges before you answer any medical questions
Visit Peptivo →If you are choosing between Hims and Peptivo, price alone will not settle it. Hims leads our six-part score, 6.8 to 5.2. One of the two has an FDA warning letter on record, covered below.
Hims vs Peptivo price
Hims publishes $199 a month. Peptivo does not post a GLP-1 price we can quote, so you would only learn its cost after an intake.
Medications and formats
Hims lists semaglutide and tirzepatide; Peptivo does not name its drug.
On format, Hims prices compounded injections and brand-name pens, while Peptivo posts no priced format.
If you want the FDA-approved brand rather than a compounded version, Hims is the only one of the two with a brand-name price.
Where each one treats patients
Hims lists 50 states, and Peptivo does not publish where it ships.
Pricing
Hims
Brand Zepbound from $299/mo medication-only; requires Hims Weight Loss Membership ($149/mo)
Peptivo
Pricing not publicly listed.
What each price covers
Both prices cover the medication itself.
Peptivo's price also covers the clinician visit and shipping, which Hims does not claim.
Hims is silent on shipping and lab work.
Peptivo is silent on lab work and coaching.
Hims
Covered by the monthly price
Medication
In the price
Clinician visits
Charged on top
Shipping
Not stated
Lab work
Not stated
Coaching
Charged on top
Peptivo
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
Where each one scores higher
Overall, Hims scores 6.8 and Peptivo 5.2 out of 10.
Hims is stronger on effectiveness (10.0 vs 5.0), trust & safety (7.0 vs 6.5) and accessibility (10.0 vs 5.0).
Peptivo is stronger on support (5.0 vs 3.0).
Value and user experience are within half a point.
Hims
6.8/10
Peptivo
5.2/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
FDA warning letters
The FDA sent Hims a warning letter dated September 9, 2025 (letter 716567), and it is still open.
Peptivo has no FDA warning letter on record with us.
Features & Coverage
| Feature | Hims | Peptivo |
|---|---|---|
| Starting Price | $199/mo | Not published |
| Features | 2 features | ✓8 features |
| States Available | 50 | Not disclosed |
| Compounded | ✓ Yes | — |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | ✓ Yes |
| FDA Warning Letters | 1 letter | ✓None |
About Hims
Hims is a major men's telehealth brand. Its weight loss offering is compounded semaglutide on a 6-month plan.
Read our full Hims review →About Peptivo
Peptivo sells its weight-loss offer as two named products rather than as drugs: 'GLP-1 Daily Support' opens at $169, 'Weight Loss Boost' at $249. Brand Ozempic, Wegovy and Zepbound can also be written. The compounded material is made in the USA at labs the site calls FDA-registered. Provider visits happen the same day and 24/7 messaging never closes. Delivery is free and discreet; FSA/HSA money qualifies. Everything is 100% online. Privacy and terms pages exist, yet nobody names the compounding pharmacy or the legal entity, and no LegitScript certification appears.
Read our full Peptivo review →Pros & Cons
Hims
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication
- Serves all 50 states
- Names 4 pharmacies that fill its prescriptions, which most sellers do not
Watch-outs
- Not included in the monthly price: clinician visits, coaching
- The FDA has issued Hims a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
Peptivo
What we like
- Shows its price before the medical questionnaire, so you can compare it without handing over health information
- The monthly price includes the medication, clinician visits and shipping
- We found no FDA warning letters issued to Peptivo
Watch-outs
- Confirm it serves your state before you start the intake
- Ask which pharmacy fills the prescription before you pay, so you can check its license
Our Verdict
Hims wins this one, 6.8 to 5.2, above all for knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC. Peptivo fits better if seeing what it charges before you answer any medical questions is your priority.
Choose Hims if…
You want knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC and an opening price near $199 a month.
Choose Peptivo if…
You want seeing what it charges before you answer any medical questions.
Ready to start? GLP-1 providers we have vetted
Telehealth providers, vetted by us, prescribing GLP-1 online.
Vetted by our editors · no insurance required
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Oak
Semaglutide at $119/month, 37% below the typical price
From $119/mo
Get started →Trimi Health
Knowing which pharmacy fills the vial: it names VialsRx
From $99/mo
Get started →ShedRx
Oral orforglipron alongside the injectables
From $149/mo
Get started →Hims vs Peptivo: FAQ
Close alternatives to Hims and Peptivo
- Hims vs Hers
- Hims vs Care Bare Rx
- Hims vs Concierge MD LA
- Hims vs Corsica Health
- Peptivo vs Embody
- Peptivo vs TrimRx
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.